Vivid Dx
Summary active Updated Jul 29, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Vivid Dx is an Oxford, UK-based precision diagnostics company developing a direct-from-blood platform that uses Raman spectroscopy and AI to detect pathogens and support phenotypic antimicrobial susceptibility testing (AST), with the goal of reducing diagnostic timelines from days to hours 12. Its work is focused on improving treatment decisions for life-threatening infections such as sepsis while helping address antimicrobial resistance. On 2026-07-28, the company announced $15 million in seed financing co-led by Oxford Science Enterprises and Cedars-Sinai Intellectual Property Co., with participation from Jameel Investment Management Company and additional strategic investors 12. Concurrent with the raise, Vivid appointed diagnostics executive Keith O’Neill as chief executive officer 12.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-28 | Seed | $15M | Oxford Science Enterprises, Cedars-Sinai Intellectual Property Co. | Jameel Investment Management Company 12 |
What Investors Say
“Vivid Dx has built strong technical proof across the core platform and is now advancing toward clinical validation.”
— Tony Besse, Principal at Oxford Science Enterprises, on the seed round 1.
“We see significant potential in Vivid Dx’s approach combining blood-based testing and AI-driven analysis.”
— Nirdesh Gupta, Managing Director at Cedars-Sinai Technology Ventures, on the seed round 1.
What Founders Say
“For decades, clinicians treating serious infections have had to wait too long for the information needed to guide antibiotic treatment.”
— Keith O’Neill, incoming CEO of Vivid Dx, on the seed round 1.
Sources
-
“Vivid Dx Raises $15M to Help Hospitals Confront One of Modern Medicine’s Most Urgent Threats: Drug-Resistant Infections,” Yahoo Finance / BusinessWire, July 28, 2026. Accessed July 2026. https://finance.yahoo.com/healthcare/articles/vivid-dx-raises-15m-help-160000212.html↩↩↩↩↩↩↩
-
“Vivid Dx Raises $15M to Advance Sepsis Diagnosis Platform, Appoints New CEO,” 360Dx, July 28, 2026. Accessed July 2026. https://www.360dx.com/business-news/vivid-dx-raises-15m-advance-sepsis-diagnosis-platform-appoints-new-ceo↩↩↩↩